{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:50:40Z","timestamp":1784076640631,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872047"],"award-info":[{"award-number":["81872047"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572430"],"award-info":[{"award-number":["81572430"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.amjms.2020.03.020","type":"journal-article","created":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T01:33:18Z","timestamp":1586050398000},"page":"339-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis"],"prefix":"10.1016","volume":"359","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0070-0907","authenticated-orcid":false,"given":"Jing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiruo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_6","key":"10.1016\/j.amjms.2020.03.020_bib0001","doi-asserted-by":"crossref","first-page":"vi22","DOI":"10.1093\/annonc\/mdp257","article-title":"Surgery and radiotherapy in the treatment of cutaneous melanoma","volume":"20","author":"Testori","year":"2009","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.amjms.2020.03.020_bib0002","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archsurg.136.8.950","article-title":"Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience","volume":"136","author":"Rose","year":"2001","journal-title":"Arch Surg"},{"key":"10.1016\/j.amjms.2020.03.020_bib0003","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.amjms.2020.03.020_bib0004","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjms.2020.03.020_bib0005","article-title":"PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8+ T cell killing","volume":"11","author":"Akhmetzyanova","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.amjms.2020.03.020_bib0006","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0007","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2012.06.013","article-title":"European consensus-based interdisciplinary guideline\u2013Update 2012","volume":"48","author":"Garbe","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjms.2020.03.020_bib0008","doi-asserted-by":"crossref","first-page":"2326s","DOI":"10.1158\/1078-0432.CCR-05-2517","article-title":"Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment","volume":"12","author":"Gajewski","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjms.2020.03.020_bib0009","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/excr.1997.3493","article-title":"Activation-induced expression of human programmed death-1 gene in T-lymphocytes","volume":"232","author":"Vibhakar","year":"1997","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.amjms.2020.03.020_bib0011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0012","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0013","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.1002729","article-title":"PDL1 expression is an independent prognostic factor in localized GIST","volume":"4","author":"Bertucci","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.amjms.2020.03.020_bib0014","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.amjms.2020.03.020_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-015-0678-7","article-title":"Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma","volume":"13","author":"Tarhini","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.amjms.2020.03.020_bib0016","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrurol.2015.287","article-title":"Prostate cancer: PD-L1 expression is common and indicates poor prognosis","volume":"13","author":"Thoma","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0017","doi-asserted-by":"crossref","first-page":"e0156323","DOI":"10.1371\/journal.pone.0156323","article-title":"Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis","volume":"11","author":"Guo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.amjms.2020.03.020_bib0018","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejso.2015.01.020","article-title":"The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Wang","year":"2015","journal-title":"EJSO"},{"key":"10.1016\/j.amjms.2020.03.020_bib0019","doi-asserted-by":"crossref","first-page":"e0131403","DOI":"10.1371\/journal.pone.0131403","article-title":"PD-L1 and survival in solid tumors: a meta-analysis","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.amjms.2020.03.020_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.amjms.2020.03.020_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"Dersimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.amjms.2020.03.020_bib0022","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.amjms.2020.03.020_bib0023","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.amjms.2020.03.020_bib0024","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.amjms.2020.03.020_bib0025","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor\u2013treated melanoma patients","volume":"21","author":"Kakavand","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjms.2020.03.020_bib0026","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites","volume":"21","author":"Kluger","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjms.2020.03.020_bib0027","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ijc.26272","article-title":"PD\u20101 expression on Melan\u2010A\u2010reactive T cells increases during progression to metastatic disease","volume":"130","author":"Kronig","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjms.2020.03.020_bib0028","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD\u2010L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti\u2010PD\u20101\/PD\u2010L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.amjms.2020.03.020_bib0029","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1093\/annonc\/mdu452","article-title":"PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics","volume":"25","author":"Massi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0030","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube J","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.amjms.2020.03.020_bib0031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/CMR.0000000000000197","article-title":"Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck","volume":"25","author":"Thierauf","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.amjms.2020.03.020_bib0032","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0033","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2020.03.020_bib0034","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0035","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2020.03.020_bib0036","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12967-016-0990-x","article-title":"Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients","volume":"14","author":"Seremet","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.amjms.2020.03.020_bib0037","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.amjms.2020.03.020_bib0038","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.amjms.2020.03.020_bib0039","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/annonc\/mdv255","article-title":"The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600","volume":"26","author":"Massi","year":"2015","journal-title":"Ann Oncol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920301129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920301129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:44:06Z","timestamp":1777380246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962920301129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0002962920301129"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2020.03.020","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2020.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}